Nifty
:
14581.45
Sensex
:
48803.68
76.65 (0.53%)
259.62 (0.53%)
Nifty
Sensex
:
:
14581.45
48803.68
76.65 (0.53%)
259.62 (0.53%)

Strides Pharma Science Ltd.

Pharmaceuticals & Drugs - Global

Rating :
51/99

BSE: 532531 | NSE: STAR

NSE BSE
854.30
15-Apr-2021
  • Open
  • High
  • Low
  • Previous Close
  •  878.00
  •  878.00
  •  850.65
  •  876.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  413052
  •  3562.08
  •  999.00
  •  322.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 7,660.55
  • 426.43
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 9,385.19
  • 1.64%
  • 2.86

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 29.67%
  • 0.00%
  • 14.01%
  • FII
  • DII
  • Others
  • 24.82%
  • 14.83%
  • 16.67%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 0.82
  • -3.76

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 6.04
  • 16.70

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 4.87
  • -40.49

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.81
  • 23.25
  • 10.38

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.99
  • 2.30
  • 1.74

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.10
  • 14.30
  • 12.61

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
832.02
732.44
13.60%
793.56
715.09
10.97%
781.80
685.80
14.00%
618.64
616.18
0.40%
Expenses
672.62
551.60
21.94%
636.35
568.50
11.93%
630.79
564.88
11.67%
553.60
523.83
5.68%
EBITDA
159.41
180.84
-11.85%
157.21
146.59
7.24%
151.01
120.92
24.88%
65.04
92.35
-29.57%
EBIDTM
19.16%
24.69%
19.81%
20.50%
19.32%
17.63%
10.51%
14.99%
Other Income
14.40
13.65
5.49%
17.75
14.07
26.15%
16.20
10.25
58.05%
17.65
16.99
3.88%
Interest
34.68
39.63
-12.49%
36.87
40.42
-8.78%
36.91
35.34
4.44%
40.33
23.36
72.65%
Depreciation
52.51
43.47
20.80%
52.79
42.00
25.69%
49.13
42.89
14.55%
45.34
29.65
52.92%
PBT
72.85
127.02
-42.65%
98.44
161.68
-39.11%
126.08
46.29
172.37%
-173.08
72.27
-
Tax
10.77
11.30
-4.69%
6.10
7.38
-17.34%
3.28
3.12
5.13%
-10.47
-7.55
-
PAT
62.07
115.72
-46.36%
92.34
154.30
-40.16%
122.80
43.17
184.46%
-162.61
79.82
-
PATM
7.46%
15.80%
11.64%
21.58%
15.71%
6.29%
-26.29%
12.95%
EPS
4.22
10.48
-59.73%
9.03
15.94
-43.35%
11.56
0.41
2,719.51%
-22.77
5.31
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Net Sales
3,026.02
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
1,195.85
1,340.96
961.76
2,550.04
1,695.84
Net Sales Growth
10.06%
-4.09%
-7.06%
-12.59%
33.68%
139.34%
-10.82%
39.43%
-62.28%
50.37%
 
Cost Of Goods Sold
1,207.93
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
560.49
714.67
491.82
1,264.39
805.65
Gross Profit
1,818.09
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
635.37
626.30
469.94
1,285.66
890.19
GP Margin
60.08%
62.35%
65.09%
58.77%
66.52%
47.51%
53.13%
46.71%
48.86%
50.42%
52.49%
Total Expenditure
2,493.36
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
967.00
1,117.54
861.18
2,059.36
1,369.22
Power & Fuel Cost
-
64.49
54.39
51.33
33.87
77.18
16.02
18.56
12.84
54.24
30.23
% Of Sales
-
2.16%
1.75%
1.53%
0.89%
2.70%
1.34%
1.38%
1.34%
2.13%
1.78%
Employee Cost
-
442.56
329.44
434.05
419.16
357.69
172.06
157.18
120.30
302.74
219.57
% Of Sales
-
14.85%
10.60%
12.98%
10.95%
12.50%
14.39%
11.72%
12.51%
11.87%
12.95%
Manufacturing Exp.
-
210.79
150.98
115.97
137.47
119.23
41.37
35.76
44.43
89.60
63.83
% Of Sales
-
7.07%
4.86%
3.47%
3.59%
4.17%
3.46%
2.67%
4.62%
3.51%
3.76%
General & Admin Exp.
-
191.89
150.10
194.38
172.63
198.71
86.25
66.37
58.16
182.12
159.16
% Of Sales
-
6.44%
4.83%
5.81%
4.51%
6.94%
7.21%
4.95%
6.05%
7.14%
9.39%
Selling & Distn. Exp.
-
137.07
111.22
208.85
161.12
129.57
61.37
66.67
39.94
116.07
88.02
% Of Sales
-
4.60%
3.58%
6.24%
4.21%
4.53%
5.13%
4.97%
4.15%
4.55%
5.19%
Miscellaneous Exp.
-
301.61
930.33
725.25
1,103.88
96.95
29.44
58.33
93.69
50.21
88.02
% Of Sales
-
10.12%
29.93%
21.69%
28.85%
3.39%
2.46%
4.35%
9.74%
1.97%
0.16%
EBITDA
532.67
510.22
296.68
235.71
516.92
380.57
228.85
223.42
100.58
490.68
326.62
EBITDA Margin
17.60%
17.12%
9.54%
7.05%
13.51%
13.30%
19.14%
16.66%
10.46%
19.24%
19.26%
Other Income
66.00
66.70
322.90
920.64
398.08
102.37
38.57
60.23
34.20
31.67
69.70
Interest
148.79
155.72
79.29
196.24
183.10
168.17
47.44
108.88
79.45
194.83
146.65
Depreciation
199.77
187.79
171.85
193.93
198.69
131.25
64.03
56.48
30.86
104.30
63.90
PBT
124.29
233.42
368.44
766.17
533.20
183.50
155.95
118.30
24.48
223.22
185.77
Tax
9.68
17.91
14.49
21.41
51.19
42.45
147.60
40.86
11.15
38.68
45.19
Tax Rate
7.79%
11.50%
3.71%
2.96%
10.30%
29.87%
99.35%
44.53%
1.54%
14.18%
24.25%
PAT
114.60
143.62
370.31
681.31
399.38
113.21
1.57
50.89
712.39
224.48
122.45
PAT before Minority Interest
125.61
137.82
375.57
701.18
445.58
99.68
0.98
50.89
713.44
234.01
141.18
Minority Interest
11.01
5.80
-5.26
-19.87
-46.20
13.53
0.59
0.00
-1.05
-9.53
-18.73
PAT Margin
3.79%
4.82%
11.91%
20.37%
10.44%
3.96%
0.13%
3.80%
74.07%
8.80%
7.22%
PAT Growth
-70.84%
-61.22%
-45.65%
70.59%
252.78%
7,110.83%
-96.91%
-92.86%
217.35%
83.32%
 
EPS
12.78
16.01
41.28
75.95
44.52
12.62
0.18
5.67
79.42
25.03
13.65

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Shareholder's Funds
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
1,006.83
2,026.24
1,371.48
1,282.78
Share Capital
89.56
89.55
89.50
89.42
89.35
59.62
59.57
58.80
58.38
57.74
Total Reserves
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
947.06
1,963.94
1,310.34
1,222.95
Non-Current Liabilities
813.65
2,342.88
2,067.29
2,048.67
2,760.03
285.79
306.42
900.59
1,132.57
2,012.89
Secured Loans
601.79
1,806.45
1,551.09
1,622.87
2,614.88
250.23
274.29
731.15
1,054.31
1,387.39
Unsecured Loans
2.12
0.06
0.23
14.84
12.13
17.16
1.24
0.00
0.00
622.45
Long Term Provisions
63.95
52.24
16.55
25.19
14.45
6.02
16.56
57.25
66.19
0.00
Current Liabilities
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
1,019.94
707.37
1,797.29
2,791.73
923.65
Trade Payables
797.75
888.99
712.07
774.09
775.40
234.41
262.31
463.08
585.04
419.85
Other Current Liabilities
354.49
248.12
129.98
819.08
347.93
502.47
127.27
651.65
1,369.80
305.00
Short Term Borrowings
1,228.78
1,339.02
944.39
1,393.96
700.48
203.03
224.56
599.89
684.65
0.00
Short Term Provisions
163.84
186.11
112.86
116.73
68.19
80.03
93.23
82.66
152.24
198.80
Total Liabilities
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
2,469.36
2,096.29
4,795.97
5,342.24
4,491.79
Net Block
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
701.36
554.53
3,016.72
3,187.64
2,328.27
Gross Block
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
1,080.55
907.33
3,514.29
3,644.82
2,626.71
Accumulated Depreciation
508.53
478.92
326.03
277.09
146.75
379.19
352.80
497.57
457.19
298.44
Non Current Assets
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
1,039.91
787.65
3,383.87
3,711.33
2,521.48
Capital Work in Progress
412.95
453.03
620.29
780.18
814.88
171.17
99.47
241.44
285.03
191.46
Non Current Investment
503.24
494.34
350.08
315.66
127.19
68.76
41.80
0.00
0.00
1.76
Long Term Loans & Adv.
208.24
223.69
197.22
222.56
201.83
96.72
90.40
118.75
229.99
0.00
Other Non Current Assets
430.77
16.86
30.72
15.62
22.62
1.91
1.45
6.96
8.67
0.00
Current Assets
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
1,410.94
1,625.27
1,960.40
Current Investments
118.97
284.75
311.48
1,279.54
1,213.76
561.29
401.24
0.06
0.00
0.00
Inventories
782.54
874.16
552.02
732.80
613.14
207.68
175.99
442.33
479.93
312.00
Sundry Debtors
931.69
987.18
882.18
995.91
1,032.97
389.96
364.00
483.23
538.44
383.78
Cash & Bank
237.10
516.65
303.33
329.48
311.59
146.88
231.15
165.74
259.73
339.45
Other Current Assets
301.81
136.87
138.84
209.70
343.44
123.64
136.26
319.58
347.17
925.17
Short Term Loans & Adv.
218.24
249.11
295.75
244.39
97.54
54.46
79.06
44.38
91.79
850.18
Net Current Assets
-172.75
386.48
584.29
687.95
1,622.91
409.50
601.26
-386.35
-1,166.46
1,036.75
Total Assets
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09
2,469.35
2,096.28
4,795.98
5,342.23
4,491.80

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Cash From Operating Activity
204.79
60.05
187.07
288.14
73.25
83.40
-271.68
134.26
457.10
323.93
PBT
48.51
344.37
705.80
497.14
146.44
992.01
2,889.87
949.49
272.69
186.37
Adjustment
527.49
94.59
-274.51
190.92
345.56
-756.73
-2,775.01
-415.93
113.84
178.94
Changes in Working Capital
-326.23
-323.14
-190.66
-341.30
-341.71
-95.91
-260.68
-310.56
128.87
-2.09
Cash after chg. in Working capital
249.76
115.82
240.63
346.76
150.29
139.37
-145.81
223.00
515.40
363.23
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-44.98
-55.76
-53.56
-58.62
-77.04
-55.97
-125.87
-88.75
-58.30
-39.29
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
1,306.16
-148.49
582.59
-686.69
-2,224.83
51.87
4,077.09
806.54
-656.47
-941.00
Net Fixed Assets
-115.07
-48.49
677.20
-236.66
-535.93
-66.57
-119.10
-38.27
-18.46
-42.91
Net Investments
-17.17
-383.09
747.64
-143.27
-1,478.58
78.09
248.81
-508.54
77.70
653.52
Others
1,438.40
283.09
-842.25
-306.76
-210.32
40.35
3,947.38
1,353.35
-715.71
-1,551.61
Cash from Financing Activity
-1,709.45
194.27
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
-990.03
89.36
850.09
Net Cash Inflow / Outflow
-198.50
105.83
-246.03
-60.33
792.35
-285.98
486.88
-49.23
-110.01
233.03
Opening Cash & Equivalents
365.89
256.16
515.08
1,110.74
298.91
586.00
132.02
211.93
325.17
79.00
Closing Cash & Equivalent
182.23
365.89
256.16
515.08
1,110.74
298.42
586.00
132.02
212.27
325.17

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Book Value (Rs.)
281.55
294.94
274.26
306.41
296.83
191.91
168.99
343.78
233.49
220.07
ROA
2.00%
5.22%
9.59%
5.79%
2.03%
0.04%
1.48%
14.07%
4.76%
3.66%
ROE
5.34%
14.74%
27.00%
16.53%
5.25%
0.09%
3.36%
42.16%
17.77%
13.87%
ROCE
6.01%
8.65%
16.07%
10.75%
7.54%
10.92%
7.76%
21.08%
12.82%
11.96%
Fixed Asset Turnover
1.50
1.17
1.04
1.27
1.47
1.21
0.61
0.27
0.82
0.72
Receivable days
70.88
79.95
102.49
96.77
90.73
114.71
114.80
193.43
65.68
86.42
Inventory Days
61.20
61.00
70.11
64.20
52.34
58.37
83.78
174.61
56.40
58.62
Payable days
138.58
146.59
116.23
117.33
75.51
76.81
112.69
253.28
92.58
119.83
Cash Conversion Cycle
-6.50
-5.64
56.37
43.64
67.55
96.27
85.89
114.76
29.50
25.22
Total Debt/Equity
0.78
1.22
1.03
1.35
1.34
0.78
0.54
0.79
1.94
1.58
Interest Cover
2.00
5.92
4.68
3.71
1.85
4.13
1.84
10.12
2.40
2.27

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011
FY 2010

News Update:


  • Strides Pharma Science’s arm, RDIF enter into partnership
    19th Mar 2021, 17:14 PM

    Stelis Biopharma and The Russian Direct Investment Fund have partnered to produce, and supply a minimum of 200 million doses of the Russian Sputnik V vaccine

    Read More
  • Strides Pharma Science’s arm receives USFDA’s approval for Potassium Chloride for Oral Solution
    15th Mar 2021, 10:21 AM

    The US market for Potassium Chloride for Oral Solution USP, 20 mEq is approximately $56 Mn

    Read More
  • Strides Pharma Science’s arm gets approval for Ibuprofen Oral Suspension
    24th Feb 2021, 11:29 AM

    The company has received approval from the United States Food & Drug Administration

    Read More
  • Strides Pharma Science’s arm gets approval for Prednisone Tablets from USFDA
    12th Feb 2021, 10:51 AM

    The US market for Prednisone Tablets USP, 10 mg and 20 mg is approximately $60 million

    Read More
  • Strides to demerge and list biotech business under Stelis Biopharma
    4th Feb 2021, 14:19 PM

    The demerger is expected to unlock significant value for Strides shareholders

    Read More
  • Strides Pharma's arm gets USFDA approval for Ursodiol Capsules
    25th Jan 2021, 14:39 PM

    The product will be manufactured at the company’s facility at Bengaluru

    Read More
  • Strides Pharma's arm gets USFDA's nod for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
    15th Jan 2021, 10:24 AM

    The company has 127 cumulative ANDA filings with USFDA of which 95 ANDAs have been approved and 32 are pending approval

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.